Characteristics and prognosis of Japanese male and female lung cancer patients: The BioBank Japan Project

Nakamura, Koshi; Ukawa, Shigekazu; Okada, Emiko; Hirata, Makoto; Nagai, Akiko; Yamagata, Zentaro; Ninomiya, Toshiharu; Muto, Kaori; Kiyohara, Yutaka; Matsuda, Koichi; Kamatani, Yoichiro; Kubo, Michiaki; Nakamura, Yusuke; Tamakoshi, Akiko

doi:10.1016/j.je.2016.12.010

Cited by 20 publications

(25 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several earlier studies on malignant neoplasms described relative survival rates after stratifying for some clinical variables, such as sex, presenting status, histological grade, and disease stage. Further detailed survival analysis on malignant neoplasms among the BBJ subjects with malignant neoplasms was also performed 27, 28, 29, 30, 31, 32. It is difficult to compare the results of relative survivals between the current and the previous studies, because of the different subject characteristics, such as ethnicity and life-style, and the differences in the health care system in other countries and the methods of enrollment used in Japan.…”

Section: Discussionmentioning

confidence: 99%

Overview of BioBank Japan follow-up data in 32 diseases

Hirata

Nagai

Kamatani

et al. 2017

Journal of Epidemiology

Self Cite

View full text Add to dashboard Cite

BackgroundWe established a patient-oriented biobank, BioBank Japan, with information on approximately 200,000 patients, suffering from any of 47 common diseases. This follow-up survey focused on 32 diseases, potentially associated with poor vital prognosis, and collected patient survival information, including cause of death. We performed a survival analysis for all subjects to get an overview of BioBank Japan follow-up data.MethodsA total of 141,612 participants were included. The survival data were last updated in 2014. Kaplan–Meier survival analysis was performed after categorizing subjects according to sex, age group, and disease status. Relative survival rates were estimated using a survival-rate table of the Japanese general population.ResultsOf 141,612 subjects (56.48% male) with 1,087,434 person-years and a 97.0% follow-up rate, 35,482 patients died during follow-up. Mean age at enrollment was 64.24 years for male subjects and 63.98 years for female subjects. The 5-year and 10-year relative survival rates for all subjects were 0.944 and 0.911, respectively, with a median follow-up duration of 8.40 years. Patients with pancreatic cancer had the least favorable prognosis (10-year relative survival: 0.184) and patients with dyslipidemia had the most favorable prognosis (1.013). The most common cause of death was malignant neoplasms. A number of subjects died from diseases other than their registered disease(s).ConclusionsThis is the first report to perform follow-up survival analysis across various common diseases. Further studies should use detailed clinical and genomic information to identify predictors of mortality in patients with common diseases, contributing to the implementation of personalized medicine.

show abstract

Section: Discussionmentioning

confidence: 99%

Overview of BioBank Japan follow-up data in 32 diseases

Hirata

Nagai

Kamatani

et al. 2017

Journal of Epidemiology

Self Cite

View full text Add to dashboard Cite

show abstract

“…In Japan, lung cancer is the leading cause of cancer-associated mortality (1). Although surgical resection is the typical treatment for stage I non-small cell lung cancer (NSCLC), the number of medically inoperable cases treated with radiotherapy has increased (2).…”

Section: Introductionmentioning

confidence: 99%

Maximum standardized uptake value on FDG-PET predicts survival in stage I non-small cell lung cancer following carbon ion radiotherapy

et al. 2017

View full text Add to dashboard Cite

Abstract. The present study (University Hospital Medical Information Network study no. UMIN000003797) aimed to evaluate whether the maximum standardized uptake value (SUV max ) of pretreatment 18 F-fluorodeoxyglucose-positron emission tomography (FDG-PET) is prognostic factor for stage I non-small cell lung cancer (NSCLC) treated with carbon ion radiotherapy (C-ion RT). Patients treated between June 2010 and June 2013 at Gunma University Heavy Ion Medical Center (Maebashi, Japan) on a prospective protocol were included in the present study. Patients with T1a-b and T2a NSCLC were treated with C-ion RT at a dose of 52.8 Gy [relative biological effectiveness (RBE)] and 60.0 Gy (RBE), respectively, in four fractions. Prior to treatment, all patients underwent FDG-PET, in which the SUV max of primary tumors was evaluated. Local control, progression-free survival (PFS), and overall survival (OS) were calculated. A total of 45 patients were analyzed and the median follow-up period was 28.9 months. The 2-year local control, PFS and OS rates for all patients were 93, 78 and 89%, respectively. The mean SUV max of primary tumors was 5.5, and patients were divided into higher (≥5.5) and lower (<5.5) SUV max groups. The 2-year PFS rates were 61 and 89% for the higher and lower SUV max groups, respectively (P=0.01), and the 2-year OS rates for the higher and lower SUV max groups were 76 and 96%, respectively (P=0.01). The higher SUV max group exhibited a significantly worse PFS and OS compared with the lower SUV max group; however, the SUV max was not associated with the local control rate. In total, 2 patients (4%) experienced grade 2 or 3 radiation pneumonitis, with their symptoms improved through conservative treatment. No patients experienced any grade 4 or 5 toxicities. The results of the present study indicate that pretreatment SUV max is a prognostic indicator for outcomes in patients with stage I NSCLC treated with C-ion RT.

show abstract

“…Only parameters kS, kE, qS, and qE, i.e., the hazard ratios of lung cancer among smokers and ex-smokers and excess hazard ratios of mortality for reasons other than lung cancer among smokers and ex-smokers, respectively, were extracted from the literature and fixed: kS=4.94, kE=2.20, qS=0.49, qE=0.20 for men and kS=4.25, kE=2.19, qS=0.51, qE=0.46 for women [14]. Other published studies from Japan yielded similar estimates [15,16,17,18,19]. All remaining rates were estimated via the following fitting procedure.…”

Section: Methodsmentioning

confidence: 99%

Predicting the Epidemiological Dynamics of Lung Cancer in Japan

Yamaguchi

Nishiura

2019

JCM

View full text Add to dashboard Cite

While the prevalence of smoking has steadily declined over time, the absolute numbers of lung cancer cases and deaths have continued to increase in Japan. We employed a simple mathematical model that describes the relationship between demographic dynamics and smoking prevalence to predict future epidemiological trends of lung cancer by age and sex. Never-smokers, smokers, and ex-smokers were assumed to experience different hazard of lung cancer, and the model was parameterized using data from 2014 and before, as learning data, and a future forecast was obtained from 2015 onwards. The maximum numbers of lung cancer cases and deaths in men will be 76,978 (95% confidence interval (CI): 76,630–77,253) and 63,284 (95% CI: 62,991–63507) in 2024, while those in women will be 42,838 (95% CI: 42,601–43,095) and 32,267 (95% CI: 32,063–32,460) in 2035 and 2036, respectively. Afterwards, the absolute numbers of cases and deaths are predicted to decrease monotonically. Our compartmental modeling approach is well suited to predicting lung cancer in Japan with dynamic ageing and drastic decline in smoking prevalence. The predicted burden is useful for anticipating demands for diagnosis, treatment, and care in the healthcare sector.

show abstract

Characteristics and prognosis of Japanese male and female lung cancer patients: The BioBank Japan Project

Cited by 20 publications

References 12 publications

Overview of BioBank Japan follow-up data in 32 diseases

Overview of BioBank Japan follow-up data in 32 diseases

Maximum standardized uptake value on FDG-PET predicts survival in stage I non-small cell lung cancer following carbon ion radiotherapy

Predicting the Epidemiological Dynamics of Lung Cancer in Japan

Contact Info

Product

Resources

About